ImmunityBio (NASDAQ:IBRX) Shares Up 15.2% – What’s Next?

ImmunityBio, Inc. (NASDAQ:IBRX)’s stock price was up 15.2% during mid-day trading on Tuesday . The stock traded as high as $7.76 and last traded at $7.67. Approximately 23,811,974 shares changed hands during mid-day trading, a decline of 39% from the average daily volume of 39,122,590 shares. The stock had previously closed at $6.66.

Key Stories Impacting ImmunityBio

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: ImmunityBio announced $75 million of non‑dilutive financing (part of $100M in financing transactions) under an amended Royalty Interest Purchase Agreement, increasing committed capital and extending the company’s runway to support commercialization and pipeline work. This reduces immediate dilution risk and is a clear near‑term liquidity positive. ImmunityBio Strengthens Balance Sheet (BusinessWire)
• Positive Sentiment: Market coverage picked up after the financing: headlines note the financing as the proximate reason shares are rising, helping explain today’s move. Watch for follow‑on analyst comments. Why Are ImmunityBio Shares Rising Today? (Benzinga)
• Positive Sentiment: TV/reactive market commentary: Jim Cramer said he would encourage owning IBRX as a speculative position, which can draw retail buying and intraday momentum. Such media endorsements often amplify volatility in small/volatile biotech names. Jim Cramer on ImmunityBio (MSN)
• Negative Sentiment: The FDA sent a warning letter over promotional claims relating to ImmunityBio’s lead biologic (Anktiva), citing misleading efficacy statements; that regulatory action triggered significant prior share weakness and elevates clinical/regulatory risk and reputational damage. This remains the primary fundamental overhang. ImmunityBio Receives FDA Warning Letter (Yahoo Finance)
• Negative Sentiment: Multiple securities class actions and investor‑rights firm notices have been filed or announced (covering purchases between Jan 19, 2026 and Mar 24, 2026) and several firms are soliciting lead‑plaintiff applications; litigation risk and potential financial exposure (legal costs, settlements) create a material overhang. Investor Alert — Robbins Geller (PR Newswire)
• Negative Sentiment: Separately, a number of law firms have opened investigations and filed complaints (including Hagens Berman, Rosen, Glancy, KSF, Faruqi and others), increasing the probability of consolidated litigation and drawing more media/regulatory attention. This prolongs uncertainty for investors. Hagens Berman Class Action Notice (PR Newswire)

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. HC Wainwright lifted their price target on ImmunityBio from $10.00 to $15.00 and gave the stock a “buy” rating in a report on Monday, February 23rd. Jefferies Financial Group lifted their target price on ImmunityBio from $8.00 to $9.00 and gave the company a “buy” rating in a research report on Friday, December 12th. Piper Sandler reiterated an “overweight” rating and set a $12.00 price target (up from $7.00) on shares of ImmunityBio in a report on Wednesday, March 4th. BTIG Research started coverage on ImmunityBio in a research report on Thursday, March 12th. They set a “buy” rating and a $13.00 price objective for the company. Finally, The Goldman Sachs Group restated a “buy” rating on shares of ImmunityBio in a report on Monday, February 23rd. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $14.40.

ImmunityBio Stock Performance

The stock’s 50-day moving average is $7.70 and its two-hundred day moving average is $4.27. The stock has a market cap of $7.89 billion, a PE ratio of -20.18 and a beta of -0.04.

ImmunityBio (NASDAQ:IBRX) last released its quarterly earnings results on Monday, February 23rd. The company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.02. The firm had revenue of $38.29 million for the quarter. Analysts forecast that ImmunityBio, Inc. will post -0.92 EPS for the current year.

Insider Buying and Selling at ImmunityBio

In related news, Director Christobel Selecky sold 25,000 shares of the stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $10.00, for a total transaction of $250,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Barry J. Simon sold 75,000 shares of the firm’s stock in a transaction dated Tuesday, February 24th. The shares were sold at an average price of $12.01, for a total value of $900,750.00. Following the transaction, the director owned 2,850,821 shares of the company’s stock, valued at $34,238,360.21. This trade represents a 2.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 501,967 shares of company stock worth $4,466,412 in the last quarter. Company insiders own 69.48% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Armistice Capital LLC purchased a new stake in ImmunityBio during the 2nd quarter worth approximately $20,497,000. Heights Capital Management Inc. purchased a new position in ImmunityBio in the 3rd quarter valued at approximately $16,152,000. Vanguard Group Inc. boosted its position in ImmunityBio by 26.8% in the 3rd quarter. Vanguard Group Inc. now owns 27,655,205 shares of the company’s stock valued at $68,032,000 after buying an additional 5,837,898 shares during the period. State Street Corp grew its stake in shares of ImmunityBio by 45.4% in the fourth quarter. State Street Corp now owns 16,455,703 shares of the company’s stock worth $32,582,000 after acquiring an additional 5,139,890 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its stake in shares of ImmunityBio by 439.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 6,152,684 shares of the company’s stock worth $12,182,000 after acquiring an additional 5,012,001 shares in the last quarter. Institutional investors and hedge funds own 8.58% of the company’s stock.

ImmunityBio Company Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.